Shots:
- The last patient is out from the P-IIb part of its multinational P-IIb/III study of NP-120 for the COVID-19 has now completed treatment with 2wk follow up
- The company reports positive interim results for the P-IIb part of it P-IIb/III Ifenprodil COVID-19 study and expecting the final data set by end of Feb 2021
- NP-120 (Ifenprodil) is an NMDA receptor antagonist specifically targeting the NMDA-type subunit 2B, & prevents glutamate signaling. The NMDA receptor is found on many tissues including lung cells, T-cells & neutrophils
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Algernon
The post Algernon’s Last Patient Out in NP-120 (Ifenprodil) P-IIb/III Study for COVID-19 first appeared on PharmaShots.
